The GLP-1 economy in five minutes: verified drug prices, and the business behind them.
Day 240.
We put a date on a prediction and promised to grade it in public whatever happened. The date is today. We got the clock wrong, and the logic never got tested, which is not the same thing as getting it right.
The call did not land.
Two hundred forty days ago, Novo Nordisk got its own cheaper copies of Ozempic and Wegovy approved in Canada. Three weeks ago we predicted when they would finally go on sale, and we put a date on it: watch the two weeks after August 5 earnings.
That window closes today. As of this morning, every one of the seventeen listings still reads Approved, not Marketed.
We promised in print to grade this call either way. Here is the grade.
We are going to work it the way a desk works a losing trade: what we called, what the market did, what we got right, what we got wrong, and what the read is now.
THE FLOOR
United States
$149 USD/mo
Wegovy pill, NovoCare
Canada
C$88 CAD/mo
Apo-Semaglutide, Costco
Set a free alert and we email you the day one of these moves, or the day a drug that has never had a price gets one. Set an alert →
Cheapest verified price we hold per market, promotional and introductory offers excluded.
The call, verbatim
THE GRADE: we predicted a launch date in print. Here is how the call did.
You grade us on what we actually printed, not on a summary we write afterwards. So here it is, quoted exactly, with links to the originals.
Edition 4, July 31, made the argument in three sentences. Read them as three separate claims, because that turns out to be the whole point of today.
They are waiting for Sevmia’s number. The twins are a pricing weapon, and you do not price your counter before the other side prints theirs.
The seven months of stillness is not indecision. It is an ambush that needs the enemy to move first.
And the calendar helps: no CFO volunteers to explain a self-cannibalizing launch on August 5, the same morning as the first down half-year in company history. Watch the two weeks after earnings.
The first two are a mechanism. The third is a date. We shipped them as one prediction.
Edition 6, August 9, put the promise in print.
One promise while the clock runs. We put a date on this call in edition 4, so the call gets graded in public.
If August 19 passes and the twins are still sitting in the database, you will read it here first, along with what we got wrong about the logic. A brief that only reports its hits is an ad.
And then the sentence right after it, which matters more today than the promise does.
The watch continues either way, because waiting for Sevmia’s number was always the core of the read, and Sevmia has not printed one yet.
Edition 7, August 12, set the terms of the grade itself. We are going to disagree with our own wording here, so it goes in whole.
So the terms are set. If the 19th passes with 17 DINs still reading Approved, the call was right on the direction and wrong on the clock, and you will read that here with the logic we got wrong laid out. If a DIN flips, you will read that first instead.
What the market did
Nothing. That is the finding.
The window we named ran 14 days from Novo’s August 5 results to today. It closed empty. No launch, no announcement, no price, no market date.
One honesty note on timing: we are publishing this grade on the morning of the deadline, with hours still on the clock.
If the twins flip today after this sends, the grade updates in this space with the timestamp, and we will have been wrong twice in one edition, once slowly and once fast.
Here is the thing about a prediction with two moving parts. Edition 4 said the twins were waiting for Sevmia’s number, and edition 4 said to watch the two weeks after earnings. Those are not one call. One is a mechanism and one is a clock, and they can fail independently.
They did.
the grade, claim by claim
| the claim | what we printed | the grade |
|---|---|---|
| the mechanism | the twins are waiting for Sevmia's number | untested, the trigger never fired |
| the timing | watch the two weeks after earnings | wrong, the window closed empty |
| the promise | the grade publishes either way | kept, you are reading it |
The clock: wrong, with no qualifier
We said the launch window opened once the CFO no longer had to explain a self-cannibalizing product on results morning, and that it ran roughly two weeks past August 5.
It ran exactly 14 days, and it ran out. That call was made, it was dated, and it failed. There is no version of this where the timing read gets partial credit.
The mechanism: untested, which is not the same as right
The core of the read was that Novo will not price its counter until the other side prints a number. The other side has still not printed one.
So the mechanism was never put to the test. The experiment did not run.
This is the part worth being careful about, because it is where a brief like this one would normally cheat. A prediction whose trigger never arrived is not vindicated. It is untested. We do not get to bank the logic because the clock ran out before the thing we said would trigger it ever happened.
Anyone telling you their thesis was proved right because the event they predicted never got the chance to occur is selling you something.
We are marking our own grade down
Edition 7 pre-committed to calling this “right on the direction and wrong on the clock.” We are not taking that grade. It is too kind to us.
“Right on the direction” implies the direction got tested. It did not. Sevmia’s silence meant the mechanism sat in the box for 51 days, and a call you never got to run is not a call you got right.
The honest grade is one miss and one untested claim.
The caveat we owe you, which cuts against us
Edition 7 promised this would land in the grade rather than in the excuse, so here it is.
Marketed status in Health Canada’s database depends on the sponsor notifying Health Canada, which is due within 30 days of first sale. A launch inside the last month could in principle not show yet.
Against that: no market date on any of the 17 DINs when we checked this morning, and no Novo Canada announcement of commercial availability. The scenario is possible and unsupported. It is a limit on our instrument, not a reason to soften the result.
The signal that survived
One thing from edition 4 did not die with the deadline.
Plosbrio’s product monograph, the official prescribing document, was revised on May 11. That is 100 days ago today. Companies do not maintain the paperwork of products they have abandoned.
That is still launch preparation without a launch. It is why Plosbrio and Poviztra stay on the board with a tripwire on them, and why we are not writing this off as a dead trade.
The read from here
What we keep
The tripwire, and it got faster. Edition 4 said we check the database weekly. That is now understated: the check runs every six hours against 20 DINs, and it reports only when something moves. The timeline carries the dated record of every check.
The device constraint, and the label it carries. Our read on the silence has not changed: pens are the constraint. Injectable generics are easy to approve and hard to manufacture at volume.
But we owe you the label that read carries: it is a working assumption, not a tested claim. It rests on two framework facts and one secondary quote about a different country.
This edition exists because we once welded an untested claim to a dated one and shipped them as a single call. We are not going to do it again in the same paragraph as the grade.
The two framework facts: Canada’s tiered pricing framework drops a three-competitor category to 25% of the brand reference price for oral solids, and only to 35% for injectables, because pens are not pills. The secondary quote: Brazil’s Hypera expects a smaller-than-usual generic discount there, citing production costs and low availability of injection pens, reported August 6.
Sevmia’s silence, promoted. For four editions Sevmia has been context: the number the twins were waiting for. At 51 days with nothing published, the silence is the story on its own.
What we change
Predictions get their trigger conditions stated separately from their timing windows.
That is the actual lesson here, and it cost us a public miss to learn. Edition 4 shipped a mechanism and a date as a single call. When the date failed, there was no clean way to say what had happened to the mechanism, because they were welded together in print.
From here they are printed separately and graded separately. A trigger condition is a claim about how the world works. A timing window is a claim about when. You can be right about one and wrong about the other, and you should have to say which.
The standing watch
The Novo v Lilly preliminary injunction motion is with Judge Zahid Quraishi, and briefing ran later than we expected. Lilly’s opposition landed August 10, a reply followed on the 17th, and five supporting declarations came in on the 17th and 18th.
So the motion went to the judge fully briefed this week rather than on the 11th. It was submitted on the papers, no hearing, no appearances. There is still no ruling of any kind on the docket. It can issue any morning without warning.
Sevmia’s window is now the lead item rather than the supporting one.
And the twins keep their tripwire, without a deadline attached to it this time.
One new thing, and it is the reason we built it. You can now put a price alert on any of these, including the ones that have never had a price. Set a watch on Plosbrio, Poviztra or Sevmia and you get an email the day a number exists for the first time, which is the exact event this edition spent 240 days failing to predict the date of. We would rather you watched the database with us than took our word for when it moves.
Downticks
the week's business, in short
The pill ceiling
Wegovy’s pill has been stuck at roughly a third of its own franchise for months, and last week it slipped from 35% to 33%. Scripts fell to about 163,000 from a high near 172,000, and the whole Wegovy franchise shrank 1.1% to roughly 495,500. Novo lost 0.7 points of the US obesity market in the same week, to 39.9% against Lilly’s 60.1%. Meanwhile Lilly’s Foundayo set a script record at 38,928 and is still climbing, while Jefferies models its quarter at $71M against $130M consensus. Records and disappointment in the same asset is what growing volume into a falling price looks like. Source: Fierce Oral GLP-1 Tracker, updated August 14.
The $675 line
Novo announced on February 24 that the US list price of Wegovy, Ozempic and Rybelsus falls to $675 a month, effective January 1, 2027, a cut of roughly 50% on Wegovy and roughly 35% on Ozempic. Its own release ring-fences the cash channel, so the $349 NovoCare price and the $149 pill are untouched by it. We are six months late to a repricing this size and it is getting the full edition it deserves; this is the verified core, from Novo’s release, on the record now rather than when we are ready.
Watching for
what moves next.
- The ruling. Fully briefed, on the papers, no hearing scheduled. It can land any morning.
- Sevmia. Day 51, no number. The first generic Wegovy’s price is still the biggest pending figure on this beat.
- The twins, now without a deadline, just a tripwire. 17 DINs, checked every six hours. We are done predicting a date. We are watching a database, and the day one flips you will read it here first.
That is the brief. Same time Sunday.